The first federal trial on claims tying prescription drug Actos to bladder cancer took a hostile turn after a judge concluded the defendants deliberately deleted key evidence.

U.S. District Judge Rebecca Doherty, citing “grave concerns” about the drug manufacturer’s conduct, sanctioned Takeda Pharmaceutical Co. Ltd. and its affiliates by ordering the jury, which heard opening statements on Feb. 3, be informed that 46 files were missing.